2025年1月22日 · Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral …

2023年11月17日 · Abelacimab is an injectable, experimental, anti-clotting medication that is categorized as a factor XI inhibitor. It has the potential to prevent the clots responsible for …

2023年11月12日 · Abelacimab is an injectable, monoclonal antibody, categorized as a factor XI inhibitor, that has the potential to prevent the clots that cause strokes and heart attacks while …

2021年7月19日 · Abelacimab (MAA868) is a fully human monoclonal antibody that binds to the catalytic domain of factor XI and locks it in the zymogen (inactive precursor) conformation, …

2024年8月15日 · Abelacimab is a novel, highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition. …

2024年8月15日 · In the ASTER trial, Anthos’ novel dual-acting Factor XI monoclonal antibody, abelacimab, is being compared to apixaban, the leading Factor Xa inhibitor, to assess their …

2025年1月22日 · Findings suggest abelacimab could transform AFib management by reducing bleeding complications and enhancing anticoagulation therapy. Clinically significant reductions …

Abelacimab Properties and Mechanism of Action. Abelacimab (MAA-868) is a humanized monoclonal immu-noglobulin G1 antibody that binds with high affinity to the catalytic domain of …

Abelacimab is a monoclonal antibody that inhibits Factor XI and the activated Factor XI (FXIa). The pharmacokinetics of abelacimab were studied in healthy subjects and patients with atrial …

2025年2月11日 · Abelacimab showed a 60-70% reduction in bleeding events compared to rivaroxaban, leading to early trial termination.